Advanz Pharma (OTCMKTS:CXRXF) issued its quarterly earnings data on Thursday. The company reported ($0.22) earnings per share for the quarter, reports. Advanz Pharma had a net margin of 322.43% and a negative return on equity of 60.90%. The company had revenue of $119.64 million during the quarter.
CXRXF opened at $10.10 on Friday. The stock’s 50 day moving average price is $12.14 and its two-hundred day moving average price is $13.63. The company has a quick ratio of 1.98, a current ratio of 2.33 and a debt-to-equity ratio of 9.26. The firm has a market capitalization of $481.79 million, a P/E ratio of 0.86 and a beta of 0.57. Advanz Pharma has a 12-month low of $9.32 and a 12-month high of $20.80.
A number of research analysts recently weighed in on the company. ValuEngine downgraded Advanz Pharma from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 2nd. Zacks Investment Research downgraded Advanz Pharma from a “hold” rating to a “sell” rating in a research note on Monday, September 16th.
ADVANZ PHARMA Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies.
Read More: Elliott Wave Theory
Receive News & Ratings for Advanz Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanz Pharma and related companies with MarketBeat.com's FREE daily email newsletter.